Logo

AKRO

Akero Therapeutics, Inc.

AKRO

Akero Therapeutics, Inc. • NASDAQ
$54.36 ▲ 0.02% (+0.01)
Market Cap $4.47 B
52w High $58.40
52w Low $21.34
Dividend Yield 0%
P/E -14.5
Volume 639.26K
Outstanding Shares 82.32M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $90.236M ▲ $-81.566M ▼ 0% $-0.99 ▼ $-80.469M ▼
Q2-2025 $0 $80.873M ▼ $-70.505M ▲ 0% $-0.86 ▲ $-69.333M ▲
Q1-2025 $0 $80.882M ▲ $-70.725M ▼ 0% $-0.9 ▲ $-69.567M ▼
Q4-2024 $0 $78.025M ▼ $-70.024M ▲ 0% $-0.99 ▲ $-68.809M ▲
Q3-2024 $0 $81.703M $-72.705M 0% $-1.05 $-71.458M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $737.826M ▼ $1.006B ▼ $47.94M ▼ $957.637M ▼
Q2-2025 $742.315M ▲ $1.109B ▼ $83.333M ▲ $1.026B ▼
Q1-2025 $686.293M ▼ $1.156B ▲ $71.997M ▼ $1.084B ▲
Q4-2024 $743.078M ▲ $825.886M ▲ $75.774M ▼ $750.112M ▲
Q3-2024 $717.247M $817.547M $79.222M $738.325M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-81.566M ▼ $-67.171M ▼ $56.781M ▼ $-34.027M ▼ $-44.417M ▼ $-67.171M ▼
Q2-2025 $-70.505M ▲ $-48.246M ▲ $79.34M ▲ $3.433M ▼ $34.527M ▲ $-48.246M ▲
Q1-2025 $-70.725M ▼ $-67.664M ▼ $-482.183M ▼ $395.531M ▲ $-154.316M ▼ $-67.664M ▼
Q4-2024 $-70.024M ▲ $-67.09M ▲ $15.272M ▼ $75.991M ▲ $24.173M ▲ $-67.09M ▲
Q3-2024 $-72.705M $-70.424M $73.067M $3.067M $5.71M $-70.424M

Five-Year Company Overview

Income Statement

Income Statement Akero is still a pure development‑stage biotech: it has no product revenue yet, so all activity shows up as research and operating expenses. Losses have grown over time as the company has advanced larger and more complex clinical trials, which is typical for a company moving from early to later‑stage studies. Per‑share losses have been relatively steady but remain sizable, reflecting a business model that is entirely focused on R&D rather than sales or profits at this stage.

Balance Sheet

Balance Sheet The balance sheet looks like that of a well‑funded clinical‑stage biotech. Total assets and cash have grown compared with earlier years, suggesting successful capital raises. Debt remains very modest, so the company is not heavily leveraged and relies mainly on equity funding. Shareholders’ equity has increased, which signals that the company has built a financial cushion to support ongoing trials, though that cushion ultimately depends on future access to capital if development runs longer than expected.

Cash Flow

Cash Flow Cash flow is consistently negative because Akero spends on research, clinical trials, and overhead without any product sales coming in. Operating and free cash outflows have gradually increased as the development program has expanded, again typical for a company in late‑stage clinical work. There is essentially no meaningful spending on physical assets, so the vast majority of cash burn is tied directly to R&D and people. The key question over time will be whether existing cash and future fundraising can comfortably cover the pace of this burn until potential approval.

Competitive Edge

Competitive Edge Akero occupies a strong niche in the emerging market for treatments for MASH, a liver disease with large unmet need. Its lead drug, efruxifermin, targets a hormone pathway that can influence several aspects of metabolic health and liver damage at once, which may differentiate it from drugs that address only one part of the disease. Early and mid‑stage trial results have shown meaningful improvements in liver scarring, including in patients with more advanced disease, which is a difficult group to treat. However, the company faces serious competition from both another FGF21 developer and from approved and late‑stage drugs with different mechanisms. This is shaping up to be a crowded but very large market, where multiple winners are possible but differentiation and safety will matter a lot.

Innovation and R&D

Innovation and R&D Innovation is the core of Akero’s story. The company is centered on a single, sophisticated drug candidate designed to be longer‑acting, more stable, and more potent than the natural hormone it mimics. Clinical data so far suggest broad benefits on liver fat, inflammation, scarring, and metabolic markers, including encouraging signs in advanced fibrosis and compensated cirrhosis. R&D is highly focused rather than spread across many programs, which can be efficient but also raises concentration risk: the company’s future depends heavily on the success of efruxifermin and its Phase 3 program. There is also optionality if the same drug can be extended into related metabolic diseases or used in combination with other therapies.

Summary

Akero is a classic late‑stage biotech: no revenue, significant and rising R&D‑driven losses, but a solid cash position and minimal debt to support an ambitious clinical agenda. Financially, the main strengths are a relatively clean balance sheet and focused spending; the main risks are continued cash burn and the need for future financing if approval and commercialization take time. Strategically, the company’s value is concentrated in one promising, differentiated asset addressing a very large disease area with substantial unmet need. Success in ongoing Phase 3 trials could transform the business, while setbacks would have an outsized impact given the lack of a broader commercial pipeline today.

NEWS

November 20, 2025 · 12:33 PM UTC

Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO

Read more

November 12, 2025 · 1:22 PM UTC

Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)

Read more

November 7, 2025 · 7:00 AM UTC

Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025

Read more

November 4, 2025 · 4:41 PM UTC

Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)

Read more

October 29, 2025 · 6:06 PM UTC

Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)

Read more